Verification of the analytical performance of the urine ecstasy immunoassay on the Abbott Alinity ci ®

The precision and reliability of the urine cannabinoids immunoassay on the Abbott Alinity ci® analyzer were systematically evaluated over 30 days in the biochemistry laboratory of Mohammed VI University Hospital. The study consisted of two phases: reproducibility assessment, involving daily measurements at low and high cannabinoid concentrations, and repeatability testing, with 30 replicates per sample. Cannabinoid quantification was performed using a homogeneous immunoenzymatic assay, with data analysis conducted via the BYG middleware, following the manufacturer's guidelines. The coefficient of variation (CV) for reproducibility ranged from 2.6% to 3.1%, while repeatability CV values varied between 2.8% and 3.7%, all within quality control limits, confirming the assay’s high precision and reliability. These findings underscore the robustness of the Alinity ci® platform for urine cannabinoid analysis, ensuring accurate and reproducible results critical for clinical and forensic applications. By adhering to rigorous analytical performance verification protocols, laboratories can ensure dependable and clinically meaningful outcomes, reinforcing the reliability of urine cannabinoid testing methodologies.